All In MedTech

Device Trial Radar · NCT07855224

Dermal Evaluation of Facetem™ S in Nasolabial Folds Esthetics Improvement: DEFINE Study

A Multicenter, Prospective, Non-randomized, Uncontrolled, Post-market Clinical Follow-up (PMCF) Study to Evaluate the Performance and Safety of Facetem™ S Dermal Fillers for the Correction of Nasolabial Folds

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Apr 2028

Study completion Jan 2029

Sponsor

Lead sponsor
CGBio Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, non-randomized, uncontrolled post-market clinical follow-up (PMCF) study designed to evaluate the performance and safety of Facetem S dermal filler for the correction of moderate-to-severe nasolabial folds in adult subjects. Subjects will receive Facetem S treatment at baseline, with an optional touch-up treatment approximately 4 weeks later if clinically necessary. Subjects will be followed for up to 12 months after the final injection to assess wrinkle severity improvement, overall aesthetic improvement, and safety.

Conditions

  • Nasolabial Folds

Interventions

  • Facetem SDevice

    Facetem S is a calcium hydroxylapatite (CaHA) dermal filler administered for the correction of moderate-to-severe nasolabial folds. Treatment will be performed in accordance with the Instructions for Use (IFU). An optional touch-up treatment may be performed approximately 4 weeks after the initial treatment if clinically necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects With ≥1-Point Improvement in WSRSTime frame: Week 12 (Week 16 for subjects receiving touch-up treatment)

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Medical office

    Cannes, France

  • MEDITI Center

    Nice, France

  • Aesthe.com

    Paris, France

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.